On October 31, 2024, NeuroSense Therapeutics Ltd., a foreign private issuer, announced the signing of a Standby Equity Purchase Agreement with YA II PN, LTD., a Cayman Islands exempt limited partnership also known as Yorkville. Under the terms of the agreement, NeuroSense has the option, but no obligation, to sell up to $30 million of its ordinary shares to Yorkville over a 36-month period. The sale price for the shares will be set at 97% of the lowest daily VWAP on the Nasdaq Stock Market over a specified three-day period following the company's notice to Yorkville. Additionally, NeuroSense has issued 224,697 ordinary shares to Yorkville as a commitment fee and paid a $25,000 structuring fee. The agreement stipulates that Yorkville's ownership cannot exceed...Show More

On October 31, 2024, NeuroSense Therapeutics Ltd., a foreign private issuer, announced the signing of a Standby Equity Purchase Agreement with YA II PN, LTD., a Cayman Islands exempt limited partnership also known as Yorkville. Under the terms of the agreement, NeuroSense has the option, but no obligation, to sell up to $30 million of its ordinary shares to Yorkville over a 36-month period. The sale price for the shares will be set at 97% of the lowest daily VWAP on the Nasdaq Stock Market over a specified three-day period following the company's notice to Yorkville. Additionally, NeuroSense has issued 224,697 ordinary shares to Yorkville as a commitment fee and paid a $25,000 structuring fee. The agreement stipulates that Yorkville's ownership cannot exceed 4.99% of NeuroSense's outstanding shares. The transaction is contingent upon the SEC declaring effective a registration statement for the shares involved. The shares are being offered under an exemption from registration requirements and are not to be sold or offered in the U.S. without registration or an applicable exemption. The agreement includes customary representations, warranties, and conditions.